EP 1235586 A1 20020904 - CONTORTROSTATIN (CN) AND METHODS FOR ITS USE IN PREVENTING METASTASIS AND OTHER CONDITIONS
Title (en)
CONTORTROSTATIN (CN) AND METHODS FOR ITS USE IN PREVENTING METASTASIS AND OTHER CONDITIONS
Title (de)
CONTORTROSTATIN (CN) UND METHODEN ZU DESSEN VERWENDUNG ZUR VERHINDERUNG VON METASTASEN UND ANDEREN PATHOGENESEN
Title (fr)
CONTORTROSTATINE (CN) ET PROCEDES D'UTILISATION DANS LA PREVENTION DE METASTASES ET D'AUTRES CONDITIONS
Publication
Application
Priority
- US 0033367 W 20001209
- US 46029599 A 19991210
- US 59155200 A 20000608
Abstract (en)
[origin: WO0141791A1] Contortrostatin, a homodimeric disintegrin, modulates the adhesion, motility, and invasiveness of integrin expressing tumor cells. When formulated as a pharmaceutically acceptable composition, the proteins can be used to treat patients by inhibiting or disrupting disease processes associated with an integrin binding to an alpha nu beta 3 or alpha nu beta 5 integrin.
IPC 1-7
IPC 8 full level
A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61P 7/02 (2006.01); A61P 9/10 (2006.01); A61P 17/02 (2006.01); A61P 19/10 (2006.01); A61P 35/04 (2006.01); A61P 43/00 (2006.01); C07K 14/47 (2006.01); C12N 5/06 (2006.01); C12N 5/07 (2010.01); C12N 5/077 (2010.01); C12N 5/09 (2010.01)
CPC (source: EP)
A61K 38/1703 (2013.01); A61P 7/02 (2017.12); A61P 9/10 (2017.12); A61P 17/02 (2017.12); A61P 19/10 (2017.12); A61P 35/00 (2017.12); A61P 35/04 (2017.12); A61P 43/00 (2017.12)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0141791 A1 20010614; WO 0141791 A9 20020704; AU 2077001 A 20010618; BR 0016488 A 20030624; CA 2393463 A1 20010614; EP 1235586 A1 20020904; EP 1235586 A4 20050803; JP 2004500357 A 20040108; MX PA02005800 A 20031014
DOCDB simple family (application)
US 0033367 W 20001209; AU 2077001 A 20001209; BR 0016488 A 20001209; CA 2393463 A 20001209; EP 00984092 A 20001209; JP 2001543135 A 20001209; MX PA02005800 A 20001209